Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is -57.23% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation.
Limited quarterly history available
ROA needs at least three reported quarters before a meaningful chart is shown.
RETURN ON ASSETS (ROA)
-57.23%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.12%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
-96.53%
vs the sector median at left
Avalyn Pharma Inc. Common Stock
Market Cap
$1.13B
Return on Assets (ROA)
-57.23%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
Return on Assets (ROA)
-48.35%
TTM Avg
-102.84%
3Y Avg
-97.55%
5Y Avg
-75.48%
Market Cap
$1.15B
Return on Assets (ROA)
-49.10%
TTM Avg
-49.10%
3Y Avg
-49.10%
5Y Avg
-49.10%
Market Cap
$1.11B
Return on Assets (ROA)
-8.93%
TTM Avg
-2.89%
3Y Avg
-5.64%
5Y Avg
-7.78%
Market Cap
$1.11B
Return on Assets (ROA)
4.50%
TTM Avg
8.06%
3Y Avg
9.38%
5Y Avg
7.83%
Market Cap
$1.16B
Return on Assets (ROA)
0.69%
TTM Avg
1.67%
3Y Avg
0.18%
5Y Avg
-3.47%
Market Cap
$1.17B
Return on Assets (ROA)
-14.35%
TTM Avg
-48.83%
3Y Avg
-54.71%
5Y Avg
-49.10%
Market Cap
$1.09B
Return on Assets (ROA)
-36.19%
TTM Avg
-21.98%
3Y Avg
-157.70%
5Y Avg
-157.70%
Market Cap
$1.09B
Return on Assets (ROA)
20.05%
TTM Avg
20.12%
3Y Avg
18.47%
5Y Avg
14.51%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $1.13B | -57.23% | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.13B | -48.35% | -102.84% | -97.55% | -75.48% |
| Kardigan, Inc. (KARD)vs › | $1.15B | -49.10% | -49.10% | -49.10% | -49.10% |
| Harrow Health, Inc. (HROW)vs › | $1.11B | -8.93% | -2.89% | -5.64% | -7.78% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.11B | 4.50% | 8.06% | 9.38% | 7.83% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.69% | 1.67% | 0.18% | -3.47% |
| Nektar Therapeutics (NKTR)vs › | $1.17B | -14.35% | -48.83% | -54.71% | -49.10% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | -36.19% | -21.98% | -157.70% | -157.70% |
| IRadimed Corporation (IRMD)vs › | $1.09B | 20.05% | 20.12% | 18.47% | 14.51% |
| MannKind Corporation (MNKD)vs › | $1.19B | -5.96% | 3.87% | -6.09% | -17.05% |
ROA
-57.2%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -57.23% |
